9/8/2022 8:49:57 AM
Lilly :Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance In Phase 3 Atopic Dermatitis Trials
8/11/2022 8:33:23 AM
Eli Lilly Says Stephen Fry, SVP, Human Resources And Diversity, Will Retire At End Of 2022
8/8/2022 6:50:14 AM
Lilly Reports Availability Of A New, Citrate-free Formulation Of Taltz Injection 80 Mg/mL
8/4/2022 6:32:09 AM
Eli Lilly And Co. (LLY) Has Lowered Its FY22 EPS Estimate To 7.90 - 8.05 From 8.15 - 8.30
8/4/2022 6:26:55 AM
Lilly Q2 EPS Down 31% To $1.05 On Reported Basis And Down 32% To $1.25 On Non-GAAP Basis
6/29/2022 6:49:22 AM
Lilly To Supply An Addnl 150K Doses Of Bebtelovimab To U.S. Government
6/29/2022 6:48:29 AM
Lilly To Supply Addl. 150K Doses Of Bebtelovimab To U.S. Govt. In Ongoing Effort To Provide COVID-19 Treatment Options
6/27/2022 3:54:40 PM
Eli Lilly And Co. (LLY) Declares $ 0.98 Dividend for Q3 22, Record Date 8/15/2022
6/27/2022 2:15:01 PM
Lilly Declares Q3 Dividend Of $0.98/share, Payable Sept. 9/ Record Aug. 15